MSMinghui Sheng

Minghui Sheng

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Minghui Sheng has a total of 14 co-authors. Here are the top co-authors by number of shared publications:

  • Dengqun Sun

    Department of General Surgery, The Chinese People’s Armed Police Forces Anhui Provincial Corps Hospital, Hefei, China

    3 shared publications
  • Zhuang Li

    Department of General Surgery, The Chinese People’s Armed Police Forces Anhui Provincial Corps Hospital, Hefei, China

    3 shared publications
  • Wenfei Wang

    Department of General Surgery, The Chinese People’s Armed Police Forces Anhui Provincial Corps Hospital, Hefei, China

    2 shared publications
  • Zhenyu Qiao

    Department of General Surgery, The Chinese People’s Armed Police Forces Anhui Provincial Corps Hospital, Hefei, China

    2 shared publications
  • Fei Xu

    Department of General Surgery, The Chinese People’s Armed Police Forces Anhui Provincial Corps Hospital, Hefei, China

    1 shared publication
  • Gencheng Han

    Beijing Institute of Basic Medical Sciences, Beijing, China

    1 shared publication

Latest Publications

  • Open Access

    Breaking age barriers: the efficacy of ERCP in advanced age patients

    by Zhuang Li, Zhenyu Qiao, Wenfei Wang, Yanjun Sun, Dengqun Sun, Minghui Sheng

    This study aims to evaluate the efficacy and safety of therapeutic endoscopic retrograde cholangiopancreatography (ERCP) in patients aged 75 years and older. A total of 723 patients who underwent ERCP at Anhui Provincial Corps Hospital of the Chinese People’s Armed Police Force between March 2018 and April 2022 were retrospectively analyzed. This cohort included 152 patients aged ≥ 75 years (elderly group) and 571 patients aged < 75 years (control group). A 1:1 propensity score matching method was used to match the baseline characteristics of gender, stone number, and stone size between the two groups to obtain a covariate balanced sample, resulting in 152 successfully matched cases. Data on comorbidities, surgical procedures, clinical outcomes, and ERCP-related complications were collected and compared between the two groups. The elderly cohort exhibited a significantly higher prevalence of comorbidities, including hypertension, diabetes, abnormal liver function, and cardiovascular and pulmonary diseases, when compared to the control group (p < 0.05). The primary indication for ERCP in both groups was choledocholithiasis. However, the elderly group had a notably higher incidence of a history of cholecystolithiasis and cholecystectomy (p < 0.05). The stone removal success rate was 95.39% (145/152) in both groups, and the difference between the groups was not statistically significant (P = 1). The rate of postoperative complications was 11.84% (18/152) in the elderly group and 18.42% (28/152) in the control group, with no significant difference observed (P = 0.11). Both groups demonstrated an improvement in quality of life scores following ERCP, with the elderly group showing significantly higher scores compared to the control group (p < 0.05). Long-term follow-up revealed that the recurrence of choledocholithiasis and cholangitis increased over time in the elderly group; however, no significant difference in recurrence rates was noted between the two groups (P > 0.05). ERCP is a safe and effective therapeutic approach for elderly patients with choledocholithiasis, associated with a low incidence of complications and favorable clinical outcomes. Given its efficacy and safety profile, ERCP should be considered a treatment of choice for elderly individuals with choledocholithiasis.


  • Matrine inhibits invasion and migration of gallbladder cancer via regulating the PI3K/AKT signaling pathway

    by Rong-Liang Mo, Zhuang Li, Peng Zhang, Ming-Hui Sheng, Gen-Cheng Han, Deng-Qun Sun

    Gallbladder cancer (GBC) is a common malignant cancer in the biliary system, which poses a serious threat to human health. It is urgent to explore ideal drugs for the treatment of GBC. Matrine is the main active ingredient of Sophora flavescentis, with a wide range of biological activities encompassing anti-inflammatory, antiviral, immunomodulatory, and anti-tumor. However, the underlying mechanism by which Matrine treats GBC is still unclear. The purpose of this study is to investigate the anti-tumor effects of Matrine on GBC in vivo and in vitro and to clarify the potential regulatory mechanisms. Here, we found that Matrine had a significant killing effect on GBC through CCK8 and flow cytometry, including arrest of cell cycle, inhibition of GBC cell, and induction of apoptosis. Further in vivo studies confirmed the inhibitory effect of Matrine on tumor growth in NOZ xenografted nude mouse. At the same time, Matrine also significantly suppressed the migration and invasion of GBC cells through scratch and Transwell experiments. In addition, by detecting the mRNA and protein levels of epithelial-mesenchymal transition (EMT) and matrix metalloproteinases, Matrine furtherly substantiated the inhibitory role on invasion and migration of GBC. From a mechanistic perspective, network pharmacology analysis suggests that the potential targets of Matrine in the treatment of GBC are enriched in the PI3K/AKT signaling pathway. Subsequently, Matrine effectively decreased the abundance of p-PI3K and p-AKT protein in vivo and in vitro. More importantly, PI3K activator (740 Y-P) antagonized the anti-tumor effect of Matrine, while PI3K inhibitor (LY294002) increased the sensitivity of Matrine for GBC. Based on the above findings, we conclude that Matrine inhibits the invasion and migration of GBC by regulating PI3K/AKT signaling pathway. Our results indicate the crucial role and regulatory mechanism of Matrine in suppressing the growth of GBC, which provides a theoretical basis for Matrine to be a candidate drug for the treatment and research of GBC.


  • Open Access

    Clinical application of indocyanine green fluorescence navigation technique in laparoscopic common bile duct exploration for complex hepatolithiasis

    by Wenfei Wang, Sanli Feng, Zhuang Li, Zhenyu Qiao, Liusheng Yang, Lin Han, Fei Xu, Xiangyu Dong, Minghui Sheng, Dengqun Sun, et al.

    Background: This study investigated the clinical application of the indocyanine green (ICG) fluorescence navigation technique in bile duct identification during laparoscopic common bile duct exploration (LCBDE) for complex hepatolithiasis. Methods: Eighty patients with complex hepatolithiasis were admitted to our department between January 2022 and June 2023 and randomly divided into control and observation groups. The control group underwent conventional LCBDE, while the observation group underwent LCBDE guided by ICG fluorescence. Results: Intraoperatively, the observation group had shorter operation and search times for the common bile duct (CBD), as well as reduced intraoperative blood loss and fewer complications, such as conversion to laparotomy and various injuries (gastroduodenal, colon, pancreatic, and vascular) than the control group, with statistical significance (P < 0.05). Postoperatively, the observation group had lower rates of postoperative bile leakage, abdominal infection, postoperative hemorrhage, and residual stone than the control group. Additionally, the observation group demonstrated significantly shorter times for resuming flatus, removal of the abdominal drainage tube, and hospitalization than the control group, with statistical significance (P < 0.05). Conclusion: ICG fluorescence navigation technology effectively visualizes the bile duct, improves its identification rate, shortens the operation time, prevents biliary tract injury, and reduces the occurrence of complications.